Access to HCV treatment in Europe

11 December 2015
EHHC, London
Svilen Konov, European AIDS Treatment Group (EATG)
Mr Svilen Konov  
European AIDS Treatment Group (EATG)

<table>
<thead>
<tr>
<th>Speaker Name</th>
<th>Statement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Svilen Konov</td>
<td>None declared</td>
</tr>
</tbody>
</table>

**COMPETING INTEREST OF FINANCIAL VALUE > £1,000:**

<table>
<thead>
<tr>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Dec 2015</td>
</tr>
</tbody>
</table>
In this presentation

- Community based research
- Some results
- How community sees access
- How some models work or do they really?
- Several musings
Community based research-EATG

• Methodology: CBOs and where no CBOs registered, individuals contacted. Data had to be confirmed by an official source
• Questionnaire with 10 questions in English and Russian
Community based research-EATG

Please provide the source of information for every of the following answers:

1. Number of people with HCV in your country:
   - Registered:
   - Estimated:
   - With HIV co-infection:

2. What treatments for HCV are used in your country?

3. What Directly Acting Antivirals (DAAs) are registered in your country?

4. Which of the DAAs are available for clinical use?

5. Are DAAs reimbursed? If not, what payment/access options are available?

6. How much does each component of the treatments cost in your country? Please list by name and provide any explanatory details if necessary.

7. How much do combination therapies (fixed dose combinations, i.e. Harvoni, etc.) cost in your country?

8. Are there any medical or other criteria on who can access DAAs? If yes, what are those criteria?

9. Do HIV co-infected people receive any priority treatment for HCV in your country?

10. Are there any early access or research programmes with DAAs in your country? If yes, what kind/with which DAAs?
Some results-34 countries

Albania, Armenia, Austria, Azerbaijan, Bosnia and Herzegovina, Bulgaria, Belarus, Switzerland, Germany, Spain, France, UK, Georgia, Greece, Croatia, Hungary, Italy, Lithuania, Latvia, Moldova, Macedonia, Netherlands, Portugal, Romania, Serbia, Sweden, Turkey, Ukraine, Russia, Kyrgyzstan, Kazakhstan, Tajikistan, Turkmenistan, Uzbekistan
Some results

- 12 countries out of the 34 do not have access to any DAAs (i.e. Macedonia, Serbia)
- 18 countries report registered DAAs, but no availability/option to use some of them in clinical practice (mainly countries from the east EU, Armenia)
- Interestingly, only 6 countries say that one can buy DAAs privately (i.e. Hungary, some countries from Central Asia)
- All countries have medical requirements for access; where 7 allow/in discussion about F2, while the rest F3-F4
- From larger countries France, Portugal, Russia, Ukraine* give priority to co-infection
How community sees the road to access

- Increase knowledge/sensitise society
- Epidemiology
- Physical access to treatments
- Prices of treatment
- Optimisation of guidelines
- Clinical programmes
- Emphasis on particular sub-populations
- Relevant research
Increase knowledge/sensitise society

In Bulgaria, they tested all participants of celebrity Big Brother in real time, prime time.
Epidemiology

• Prices of testing
• Gaps and lacks of unified surveillance systems (i.e. The Netherlands-no registry for HCV mono-infection, Germany-estimations, UK-estimations)
Physical access to treatments

• Registration does not mean access
• Once registered, the medicine needs to be included in the list of the “life-important medicines”
• Once included, it needs a price registration and a tender
• Then, it is centrally (maybe totally decentralised in some countries) distributed to the clinics
Prices

• Spain: With regard to drug pricing, there are two prices, namely the list price of EUR 40,000 per patient treated (irrespective of the treatment duration), and then there is a price for the reimbursement system which is not public. The price should fall alongside with the increase in the number of patients. As an example, with 50,000 patients, it should fall to approximately 6 000 EUR per cure.
Prices

- The Netherlands: Sovaldi 14,280 Euros/tablet 400 mg (28). Olysio 2,080.54 Euros/capsule 150 mg (7), Daklinza 314,58 Euros/tablet 60 mg
- Switzerland: Sovaldi 400 mg (28) 18,441.50 Euros, Olysio 150 mg (7) 2,783.40 Euros, Harvoni (28) 19,957.70 Euros
# Prices of treatments

<table>
<thead>
<tr>
<th>Marketing Company</th>
<th>Brand name</th>
<th>Gilead Licensee</th>
<th>Manufacturer</th>
<th>Printed price, USD*</th>
<th>Market price, USD*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Abbott India Limited</td>
<td>Viroclear</td>
<td>No</td>
<td>Hetero Laboratories Limited</td>
<td>$339</td>
<td>$226</td>
</tr>
<tr>
<td>2 Biocon</td>
<td>Cimivir</td>
<td>Yes</td>
<td>Hetero Laboratories Limited</td>
<td>$322</td>
<td>$226</td>
</tr>
<tr>
<td>3 Cipla Limited</td>
<td>Hepcvir</td>
<td>Yes</td>
<td>Hetero Laboratories Limited</td>
<td>$321</td>
<td>$177</td>
</tr>
<tr>
<td>4 Dr Reddy’s Laboratories</td>
<td>Resof</td>
<td>No</td>
<td>Hetero Laboratories Limited</td>
<td>$322</td>
<td>$226</td>
</tr>
<tr>
<td>5 Emcure Pharmaceuticals Limited</td>
<td>Spegra</td>
<td>No</td>
<td>Natco Pharma Limited</td>
<td>$321</td>
<td>$161</td>
</tr>
<tr>
<td>6 Hetero Healthcare Limited</td>
<td>Sofovir</td>
<td>Yes</td>
<td>Hetero Laboratories Limited</td>
<td>$314</td>
<td>$193</td>
</tr>
<tr>
<td>7 Mylan Pharmaceuticals Private Limited</td>
<td>Sovaldi</td>
<td>N/A</td>
<td>Gilead Sciences</td>
<td>$321</td>
<td>$319</td>
</tr>
<tr>
<td>8 Mylan Pharmaceuticals Private Limited</td>
<td>MyHep</td>
<td>Yes</td>
<td>Natco Pharma Limited</td>
<td>$321</td>
<td>$193</td>
</tr>
<tr>
<td>9 Natco Pharma Limited</td>
<td>Hepcinat</td>
<td>Yes</td>
<td>Natco Pharma Limited</td>
<td>$321</td>
<td>$313</td>
</tr>
<tr>
<td>10 Ranbaxy Laboratories</td>
<td>Sofab</td>
<td>Yes</td>
<td>Hetero Laboratories Limited</td>
<td>$321</td>
<td>$258</td>
</tr>
<tr>
<td>11 Strides Arcolab Limited</td>
<td>Virso</td>
<td>Yes</td>
<td>Natco Pharma Limited</td>
<td>$321</td>
<td>$177</td>
</tr>
<tr>
<td>12 Zydus Heptiza</td>
<td>SoviHep</td>
<td>Yes</td>
<td>Natco Pharma Limited</td>
<td>$321</td>
<td>$258</td>
</tr>
<tr>
<td>13 Aurobindo Pharma</td>
<td>TBD</td>
<td>Yes</td>
<td>TBD</td>
<td>TBD</td>
<td>N/A</td>
</tr>
<tr>
<td>14 Laurus Laboratories</td>
<td>TBD</td>
<td>Yes</td>
<td>TBD</td>
<td>TBD</td>
<td>N/A</td>
</tr>
<tr>
<td>15 Sequent</td>
<td>TBD</td>
<td>Yes</td>
<td>TBD</td>
<td>TBD</td>
<td>N/A</td>
</tr>
</tbody>
</table>

*Printed prices were obtained from bottle labels. Market prices are based on community procurement costs in Northeast India. Prices in other locations and through other suppliers may differ. All prices are for one 28-pill bottle and in approximate USD (1 USD=62 Indian Rupees).
Optimisation of guidelines/national plans

• National plans
• EACS
• EASL
• Work with Russia
Clinical care, sub-populations, relevant research

• Who provides me with care? Specialist vs. primary care physician; where do I get the care?

• How about the drug-users, inmates, people with advanced cirrhosis, pre- and post-transplant, GT3

• Cross-company collaborations
How some models work or do they really?

Всем здравствуйте,

Уже более месяца в Узбекистане можно купить генерический софосбувир в аптеках. Мало кто об этом знает.

Стоимость: 1 400 000 сум за упаковку. Сейчас это составляет около 250$

Телефон одной из аптек, продающих софосбувир в Ташкенте: XXX XX XX

С уважением,

XXXXXXX XXXXXX
Some musings

• Evolution vs. devolution
Thank you!

svilen.konov@sevt.info